Navigation Links
Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium
Date:1/20/2012

efore having Oncotype DX testing, physicians changed treatment recommendations based on the Recurrence Score results in 27 patients (29 percent).  Two-thirds (67 percent) of changes in treatment recommendations were decreases in treatment intensity (changes from chemotherapy to observation or from oxaliplatin-containing chemotherapy to treatment with fluoropyrimidine monotherapy), while one-third (33 percent) of changes were increased treatment intensity.

"In the past, selection of stage II patients for chemotherapy treatment following surgery has been based on a limited set of clinical and pathologic markers that are uninformative for most patients," said Thomas H. Cartwright, M.D., Ocala Oncology, Ocala, Florida, and the principal investigator of this study. "The Oncotype DX colon cancer test has been clinically validated as a predictor of individual recurrence risk for stage II colon cancer patients, providing quantitative information about recurrence risk which has not been available with conventional measures.   The test is now being used in treatment planning by physicians and patients worldwide, and represents an important advancement in bringing personalized medicine into today's clinical setting to benefit patients."

The new clinical decision-making data adds to the growing list of recent colon cancer milestones achieved by Genomic Health including:

  • Publication of the positive results from the landmark QUASAR clinical validation study in the Journal of Clinical Oncology, which established that the Oncotype DX colon cancer test predicts recurrence risk in stage II colon cancer patients following surgery and provides additional clinical value beyond conventional measures such as T-stage, mismatch repair (MMR) status, nodes examined, grade and lymphovascular invasion;
  • Obtained Medicare coverage policy for the Oncotype DX colon cancer test, which ensu
    '/>"/>

SOURCE Genomic Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
2. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
3. Genomic Technologies: Market Insights for Life Science Suppliers
4. SwitchGear Genomics and New England Biolabs Develop New Multiplex Reporter Assay System
5. Synthetic Genomics Inc. and Plenus, S.A. de C.V. Form New Sustainable Agriculture Company, Agradis, Inc. to Develop and Commercialize Products Using Genomic Technologies
6. New England Biolabs and Rubicon Genomics Enter into Distribution Agreement for Single Cell Amplification Products
7. Center for Proteomics at the Translational Genomics Research Institute (TGen) Selected as Waters Center of Innovation
8. Transgenomic Reports Second Quarter Financial Results
9. ACMG Announces New Online Live Learning Center: Will Bring Genetics and Genomics Education to Varied Health Professionals
10. Quest Diagnostics and Genomic Vision Form Strategic Collaboration to Develop Genome-based Laboratory Tests
11. Clinical Genomics Extends Strategic Alliance for Colorectal Cancer Testing Development with Quest Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... ... its GHS Label Guide . To align chemical container labeling with OSHA’s ... includes explanations of label components, an example of an accurate label, and pictogram ...
(Date:7/29/2015)... 29, 2015  Therapath Neuropathology ( www.Therapath.com ), ... with VA and Military Medical centers both domestically ... (ENFD) and Sweat Gland Nerve Fiber Density (SGNFD) ... https://therapath.com/skin ). Demonstration of a ... on punch skin biopsy is a highly sensitive ...
(Date:7/29/2015)... 2015  Indivior PLC (LON: INDV) today announced that ... was accepted and received Priority Review by the U.S. ... opioid overdose. This naloxone nasal spray comes as a ... absorption into the nasal mucosa. 1 The device ... may be better equipped to help an opioid overdose ...
(Date:7/29/2015)... 29, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... company, is pleased to announce that the final design ... been locked.  Prototypes for industrial and regulatory testing ... application for CE mark clearance to market the ... 2016. (Photo: http://photos.prnewswire.com/prnh/20150729/248373 )  ...
Breaking Biology Technology:Brady Announces a New GHS Label Guide 2Neuropathology services for VA and Military health systems 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5
... PALO ALTO, Calif., Sept. 19 Telik, Inc.,(Nasdaq: ... corporate,overview at the UBS Global Life Sciences Conference in ... p.m. Eastern time (9:30 a.m. Pacific,time). Telik,s presentation will ... the Telik website, http://www.telik.com, through October 3,2007. ...
... 19 NPS,Pharmaceuticals, Inc. (Nasdaq: NPSP ) ... Office of Orphan Products Development has granted,orphan drug ... for the treatment of hypoparathyroidism, a rare deficiency ... therapy. Hypoparathyroidism afflicts approximately 65,000 people in ...
... (Nasdaq: SGMO ) announced today that Edward Lanphier,Sangamo,s ... on,the progress of Sangamo,s ZFP Therapeutic development programs and ... (ET) on Wednesday,September 26, 2007 at the UBS 2007 ... will be webcast live and may be accessed via ...
Cached Biology Technology:PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism 2PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism 3Sangamo BioSciences to Present at the UBS Global Life Sciences Conference 2
(Date:7/20/2015)... 2015  Acuity Market Intelligence,s latest research "The ... Commerce and Privacy" forecasts that between 2014 and ... be downloaded to smart mobile devices by 2.2 ... is projected to generate more than $67.9 billion ... forecast period.    "Biometrics is at ...
(Date:7/13/2015)... 13, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, ... 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND ... and secure method to make payments.  With this ... introduced with its groundbreaking voice-direct payment patent application, ...
(Date:7/9/2015)... DUBLIN , July 07, 2015 ... has announced the addition of the "Biometrics ... and Forecasts 2015-2020" report to their offering. ... a major contributor to this growth and the ... US$5.5 billion in revenue for companies involved in ...
Breaking Biology News(10 mins):Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... line all the cavities and free,surfaces of the body, ... in the body organs. The organized structure of normal ... cancer, according to a,study by University of Helsinki scientists. ... the Proceedings of the National Academy of Sciences,(PNAS). ...
... have designed a nanoscale system to observe and ... By combining microfabricated cantilevers and magnetic ... study showed that cells respond to outside forces ... and their environment. The study also revealed that ...
... discovered why a bacterial lung infection is so lethal ... authorities had thought, according to research published August 23 ... first time that a toxin released by bacteria causes ... pneumonia. It is the bleeding, the authors argue, not ...
Cached Biology News:Cells united against cancer 2Bioengineers at University of Pennsylvania devise nanoscale system to measure cellular forces 2Bleeding, not inflammation, is major cause of early lung infection death 2Bleeding, not inflammation, is major cause of early lung infection death 3
The VersArray hybridization chamber is used for manual (coverslip) hybridization of microarrays. The chamber accommodates 2 slides and is watertight to allow incubation of slides in a water bath. Dim...
... The Eclipse is a state-of-the-art separation ... Fractionation (AFFF) technique. The Eclipse integrates easily ... DAWN, miniDAWN Tristar, as well as the ... size and molar mass distributions of the ...
Monoclonal antibodies conjugated with rhodamine...
... Moticam 2300 camera (MC2300) attaches to virtually ... trinocular port. Included in the standard package, ... software offers quick and accurate image capture, ... for examination or documentation purposes. The MC2300s ...
Biology Products: